Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

ZhaoMin Liu

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
JMIR Aging|November 21, 2023
A Machine Learning-Based Preclinical Osteoporosis Screening Tool (POST): Model Development and Validation StudyQingling Yang, Huilin Cheng, Jing Qin, et al.
Cancer Cell|November 13, 2019
A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In VivoLongchuan Bai, Haibin Zhou, Renqi Xu, et al.
Journal of Medicinal Chemistry|November 21, 2019
Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 ProteinHaibin Zhou, Longchuan Bai, Renqi Xu, et al.
Journal of Medicinal Chemistry|July 1, 2021
Discovery of M-1121 as an Orally Active Covalent Inhibitor of Menin-MLL Interaction Capable of Achieving Complete and Long-Lasting Tumor RegressionMeng Zhang, Angelo Aguilar, Shilin Xu, et al.
Science Translational Medicine|December 18, 2024
The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipronKyle W Sloop, Amy L Cox, David B Wainscott, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
JMIR Aging|November 21, 2023
A Machine Learning-Based Preclinical Osteoporosis Screening Tool (POST): Model Development and Validation StudyQingling Yang, Huilin Cheng, Jing Qin, et al.
Cancer Cell|November 13, 2019
A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In VivoLongchuan Bai, Haibin Zhou, Renqi Xu, et al.
Journal of Medicinal Chemistry|November 21, 2019
Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 ProteinHaibin Zhou, Longchuan Bai, Renqi Xu, et al.
Journal of Medicinal Chemistry|July 1, 2021
Discovery of M-1121 as an Orally Active Covalent Inhibitor of Menin-MLL Interaction Capable of Achieving Complete and Long-Lasting Tumor RegressionMeng Zhang, Angelo Aguilar, Shilin Xu, et al.
Science Translational Medicine|December 18, 2024
The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipronKyle W Sloop, Amy L Cox, David B Wainscott, et al.
Pageof 6